Literature DB >> 16139398

Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis.

Norah J Shire1, Jeffrey A Welge, Kenneth E Sherman.   

Abstract

Patients with human immunodeficiency virus-1 (HIV) have elevated risk for hepatitis A virus (HAV) coinfection. Sequelae from coinfection include increased risk of liver-related morbidity and mortality. This study synthesizes the results of trials measuring response to HAV vaccine in HIV-infected patients using Bayesian meta-analysis methodologies. PubMed, OhioLINK/Medline, and other sources were used to search for studies analyzing response to HAV vaccine in HIV-infected patients. Studies were evaluated for quality. A Bayesian hierarchical random-effects model was used to estimate overall response to vaccine. Between-study variance was calculated. Sensitivity analyses were conducted to determine the potential for bias. The literature search yielded eight studies for inclusion in the meta-analysis, with a combined total of 458 patients. Observed proportions of response in individual studies ranged from 50 to 95%. The intention-to-treat meta-analysis estimated a combined proportion of HIV+ patients responding to vaccine of 64% (95% CI 52-75%). Heterogeneity between studies was significant. The overall response rate to HAV vaccine in HIV-infected patients is lower than typically cited. Up to 1/2 of HIV-infected patients may be nonresponders. Future research will be required to better understand the correlates of response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139398     DOI: 10.1016/j.vaccine.2005.07.102

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

Review 2.  HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches.

Authors:  Mohammad Khalid Parvez
Journal:  World J Hepatol       Date:  2015-01-27

3.  Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men.

Authors:  Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Naomi Jay; David Aboulafia; David L Cohn; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

4.  Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Kenneth Wilkins; Andrew W Lee; Anthony Grosso; Michael L Landrum; Amy Weintrob; Anuradha Ganesan; Jason Maguire; Stephanie Klopfer; Carolyn Brandt; William P Bradley; Mark R Wallace; Brian K Agan
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

5.  Determinants of hepatitis A vaccine immunity in a cohort of human immunodeficiency virus-infected children living in Switzerland.

Authors:  Pierre Alex Crisinel; Klara Maria Posfay-Barbe; Christoph Aebi; Jean-Jacques Cheseaux; Christian Kahlert; Christoph Rudin; David Nadal; Claire-Anne Siegrist
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

Review 6.  Human papillomavirus vaccination in HIV-infected women: need for increased coverage.

Authors:  Erna Milunka Kojic; Aadia I Rana; Susan Cu-Uvin
Journal:  Expert Rev Vaccines       Date:  2015-11-24       Impact factor: 5.217

7.  Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.

Authors:  Erna Milunka Kojic; Minhee Kang; Michelle S Cespedes; Triin Umbleja; Catherine Godfrey; Reena T Allen; Cynthia Firnhaber; Beatriz Grinsztejn; Joel M Palefsky; Jennifer Y Webster-Cyriaque; Alfred Saah; Judith A Aberg; Susan Cu-Uvin
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

8.  Clinical factors associated with hepatitis A virus seropositivity in HIV-infected adults living in a country with an epidemiologic shift for hepatitis A virus infection.

Authors:  Ji Hyeon Baek; Chang Oh Kim; Jun Yong Park; Su Jin Jeong; Nam Soo Koo; Hye Won Kim; Sang Hoon Han; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

9.  Humoral and cell-mediated immune responses after a booster dose of HBV vaccine in HIV-infected children, adolescents and young adults.

Authors:  Vania Giacomet; Michela Masetti; Pilar Nannini; Federica Forlanini; Mario Clerici; Gian Vincenzo Zuccotti; Daria Trabattoni
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

Review 10.  Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review.

Authors:  Kuan-Yin Lin; Guan-Jhou Chen; Yu-Lin Lee; Yi-Chia Huang; Aristine Cheng; Hsin-Yun Sun; Sui-Yuan Chang; Chun-Eng Liu; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.